BIODLINK-B

1875
3.4702.36% ( +0.080 )
Delay Closed: Nov 16, 16:08:00

Profile

About

BIODLINK-B
BIODLINK-B
01875.HK

BioDlink International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat metastatic colorectal cancer; advanced, metastatic or recurrent non-small cell lung cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer; fallopian tube cancer or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule for the treatment of glioblastoma and anaplastic astrocytoma. In addition, the company develops TAB014 a bevacizumab ophthalmic drug for the treatment of wet age-related macular degeneration (wAMD).

Profile

Company Name
BioDlink International Company Limited
Market
SEHK
Founded
Industry
--
Fiscal Year End
December 31

Related Securities

Industry

Management